Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to ...

Incyte filed a lawsuit to try to block the launch of Leqselvi, claiming that the drug infringed a US patent (No. 9,662,335) ...

Incyte reported strong Q3 revenue growth, mainly driven by Jakafi and Opzelura, with a 24% increase year-over-year. Find out ...

To help foot the bill to launch its approved graft-versus-host disease drug Niktimvo and the expected launch of its leukemia treatment revumenib, Syndax has struck a $350 million licensing deal with ...

On Tuesday, Incyte Corporation (NASDAQ:INCY) reported third-quarter revenue of $1.14 billion, up 24% year over year, beating ...

Shares of Incyte (NASDAQ:INCY) jumped 8% after the company reported better-than-expected Q3 revenue and raised sales guidance ...

Incyte (Nasdaq: INCY) announced today that it will present at the following investor conferences during the month of November ...

Incyte delivered robust third-quarter revenue growth, surpassing expectations, despite increased operational costs.

Shares of Incyte Corp. INCY inched 0.11% higher to $65.24 Thursday, on what proved to be an all-around mixed trading session ...

In a report released today, Marc Frahm from TD Cowen maintained a Buy rating on Incyte (INCY – Research Report), with a price target of ...

The Company presented interim results from the TAMARACK study at the European Society for Medical Oncology (ESMO) Congress in September 2024 and expects to have mature median radiographic ...

Shares of Incyte Co. (NASDAQ:INCY – Get Free Report) have been assigned an average recommendation of “Hold” from the twenty-one brokerages that are covering the company, Marketbeat.com reports. One ...